BRYAN HYLER: Open Payments
NPI 1811218092 · VISTA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,150 in 44 payments from 11 companies in 2025. Trend: 2023 $3,546 · 2024 $2,824 · 2025 $2,150
Food & beverage: $2,150
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $485 |
| Alkermes, Inc. | 5 | $379 |
| Neurocrine BioSciences, Inc. | 2 | $244 |
| Axsome Therapeutics, Inc. | 3 | $239 |
| Otsuka America Pharmaceutical, Inc. | 5 | $183 |
| Vanda Pharmaceuticals Inc. | 2 | $135 |
| ABBVIE INC. | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $121 |
| Lilly USA, LLC | 1 | $116 |
| Janssen Pharmaceuticals, Inc | 1 | $106 |
Products named: CAPLYTA, INGREZZA, LYBALVI, Auvelity, REXULTI, ARISTADA, FANAPT, VRAYLAR.
Industry payments across CA — which companies pay providers there.
